<?xml version="1.0" encoding="UTF-8" standalone="no"?><?xml-stylesheet type="text/css" href="uslm.css"?><pLaw xmlns="http://schemas.gpo.gov/xml/uslm" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" xsi:schemaLocation="http://schemas.gpo.gov/xml/uslm https://www.govinfo.gov/schemas/xml/uslm/uslm-2.0.17.xsd">

<?I97 ??>
<?I50 PUBLIC LAW 119–26—JULY 16, 2025?>


<?I97 139 STAT. ?>
<?I98 139 STAT. ?>
<?I99 139 STAT. ?>
<?I50 PUBLIC LAW 119–26—JULY 16, 2025?>
<?I51 PUBLIC LAW 119–26—JULY 16, 2025?>
<?I52 PUBLIC LAW 119–26—JULY 16, 2025?>


<!--Disclaimer: Legislative measures that include compacts or other non-standard data structures will require additional modeling and may contain inconsistencies in the converted USLM XML.-->
<meta><dc:title>Public Law 119–26: To amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes.</dc:title>
<dc:type>Public Law</dc:type><docNumber>26</docNumber>
<citableAs>Public Law 119–26</citableAs><citableAs>139 Stat. 410</citableAs>
<approvedDate>2025-07-16</approvedDate>
<dc:date>2025-07-16</dc:date>
<dc:publisher>United States Government Publishing Office</dc:publisher><dc:creator>National Archives and Records Administration</dc:creator><dc:creator>Office of the Federal Register</dc:creator><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<processedBy>GPO Locator to USLM Converter 4.12.3;Stage2.20240826</processedBy><processedDate>2025-07-30</processedDate>
<congress>119</congress><publicPrivate>public</publicPrivate>
</meta>
<preface><page display="no">?409</page><note role="coverPage"><centerRunningHead>PUBLIC LAW 119–26—JULY 16, 2025</centerRunningHead>
<coverTitle>HALT ALL LETHAL TRAFFICKING OF FENTANYL ACT</coverTitle>
</note>
<page identifier="/us/stat/139/410">139 STAT. 410</page>
<dc:type>Public Law</dc:type><docNumber>119–26</docNumber>
<congress value="119">119th Congress</congress>
</preface>
<main>
<longTitle>
<docTitle class="centered fontsize12" style="-uslm-lc:I658005">An Act</docTitle>
<officialTitle class="indentUp0 firstIndent1 fontsize8" style="-uslm-lc:I658011">To amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes.<sidenote><p class="centered fontsize8" id="x62def56a-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658076"><approvedDate date="2025-07-16">July 16, 2025</approvedDate></p><p class="centered fontsize8" id="x62def56b-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658076">[<ref href="/us/bill/119/s/331">S. 331</ref>]</p></sidenote><?GPOvSpace 08?></officialTitle>
</longTitle>
<enactingFormula style="-uslm-lc:I658120"><i>  Be it enacted by the Senate and House of Representa­tives of the United States of America in Congress assembled,</i></enactingFormula><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62df1c7c-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Halt All Lethal Trafficking of Fentanyl Act.</p></sidenote>
<section id="d648e98" identifier="/us/pl/119/26/s1" style="-uslm-lc:I658146"><num class="bold" value="1">SECTION 1. </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62df1c7d-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t21/s801">21 USC 801 note</ref>.</p></sidenote><heading>SHORT TITLE.</heading><content style="-uslm-lc:I658120">  This Act may be cited as the “<shortTitle role="act">Halt All Lethal Trafficking of Fentanyl Act</shortTitle>” or the “<shortTitle role="act">HALT Fentanyl Act</shortTitle>”.</content></section>
<section id="d648e116" identifier="/us/pl/119/26/s2" role="instruction" style="-uslm-lc:I658141"><num class="fontsize12" value="2">SEC. 2. </num><heading>CLASS SCHEDULING OF FENTANYL-RELATED SUBSTANCES.</heading><content class="firstIndent0 fontsize10" id="x62df6a9e-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120">  Section 202(c) of the Controlled Substances Act (<ref href="/us/usc/t21/s812/c">21 U.S.C. 812(c)</ref>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end of schedule I the following:<quotedContent><subsection class="firstIndent0 fontsize10" id="y62dfdfcf-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="e">“(e)</num><paragraph class="inline" id="y62dfdfd0-6d77-11f0-a6a6-a93fc28e9cb7"><num value="1">(1) </num><content>Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a fentanyl-related substance, or which contains the salts, isomers, and salts of isomers of a fentanyl-related substance whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.</content></paragraph><paragraph class="indentUp0 firstIndent0 fontsize10" id="y62dfdfd1-6d77-11f0-a6a6-a93fc28e9cb7" role="definitions" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">“(2) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62dfdfd2-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Definition.</p></sidenote><chapeau>For purposes of paragraph (1), except as provided in paragraph (3), the term ‘<term>fentanyl-related substance</term>’ means any substance that is structurally related to fentanyl by 1 or more of the following modifications:</chapeau><subparagraph class="fontsize10" id="y62dfdfd3-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>By replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle.</content></subparagraph><subparagraph class="fontsize10" id="y62dfdfd4-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>By substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups.</content></subparagraph><subparagraph class="fontsize10" id="y62dfdfd5-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">“(C) </num><content>By substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups.</content></subparagraph><subparagraph class="fontsize10" id="y62dfdfd6-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="D">“(D) </num><content>By replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle.</content></subparagraph><subparagraph class="fontsize10" id="y62dfdfd7-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="E">“(E) </num><content>By replacement of the N-propionyl group with another acyl group.</content></subparagraph></paragraph><paragraph class="indentUp0 firstIndent0 fontsize10" id="y62dfdfd8-6d77-11f0-a6a6-a93fc28e9cb7" role="definitions" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">“(3) </num><chapeau>A substance that satisfies the definition of the term ‘<term>fentanyl-related substance</term>’ in paragraph (2) shall nonetheless not be treated as a fentanyl-related substance subject to this schedule if the substance—</chapeau><subparagraph class="fontsize10" id="y62dfdfd9-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>is controlled by action of the Attorney General under section 201; or<page identifier="/us/stat/139/411">139 STAT. 411</page></content></subparagraph><subparagraph class="fontsize10" id="y62dfdfda-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>is otherwise expressly listed in a schedule other than this schedule.</content></subparagraph></paragraph><paragraph class="indentUp0 firstIndent0 fontsize10" id="y62dfdfdb-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="4">“(4)</num><subparagraph class="inline" id="y62dfdfdc-6d77-11f0-a6a6-a93fc28e9cb7" role="definitions"><num value="A">(A) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62dfdfdd-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Federal Register, publication.</p><p class="leftAlign firstIndent0 fontsize8" id="x62dfdfde-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">List.</p></sidenote><content>The Attorney General may by order publish in the Federal Register a list of substances that satisfy the definition of the term ‘<term>fentanyl-related substance</term>’ in paragraph (2).</content></subparagraph><subparagraph class="indentUp0 firstIndent0 fontsize10" id="y62dfdfdf-6d77-11f0-a6a6-a93fc28e9cb7" role="definitions" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>The absence of a substance from a list published under subparagraph (A) does not negate the control status of the substance under this schedule if the substance satisfies the definition of the term ‘<term>fentanyl-related substance</term>’ in paragraph (2).”</content></subparagraph></paragraph></subsection></quotedContent>.</content></section>
<section id="d648e200" identifier="/us/pl/119/26/s3" style="-uslm-lc:I658141"><num class="fontsize12" value="3">SEC. 3. </num><heading>REGISTRATION REQUIREMENTS RELATED TO RESEARCH.</heading><subsection class="firstIndent0 fontsize10" id="y62e202c0-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/a" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10 smallCaps">Alternative Registration Process for Schedule I Research<inline class="noSmallCaps">.—</inline></heading><chapeau>Section 303 of the Controlled Substances Act (<ref href="/us/usc/t21/s823">21 U.S.C. 823</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="y62e202c1-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/a/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>by <amendingAction type="redesignate">redesignating</amendingAction> the second subsection (l) (relating to required training for prescribers) as subsection (m); and</content></paragraph><paragraph class="fontsize10" id="y62e202c2-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/a/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subsection class="indentDown1 firstIndent0 fontsize10" id="y62e31433-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="n">“(n) </num><heading class="fontsize10 smallCaps">Special Provisions for Practitioners Conducting Certain Research With Schedule I Controlled Substances<inline class="noSmallCaps">.—</inline></heading><paragraph class="fontsize10" id="y62e31434-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">“(1) </num><heading class="fontsize10 smallCaps">In general<inline class="noSmallCaps">.—</inline></heading><content>Notwithstanding subsection (g), a practitioner may conduct research described in paragraph (2) of this subsection with 1 or more schedule I substances in accordance with subparagraph (A) or (B) of paragraph (3) of this subsection.</content></paragraph><paragraph class="fontsize10" id="y62e31435-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">“(2) </num><heading class="fontsize10 smallCaps">Research subject to expedited procedures<inline class="noSmallCaps">.—</inline></heading><chapeau>Research described in this paragraph is research that—</chapeau><subparagraph class="fontsize10" id="y62e31436-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>is with respect to a drug that is the subject of an investigational use exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<ref href="/us/usc/t21/s355/i">21 U.S.C. 355(i)</ref>); or</content></subparagraph><subparagraph class="fontsize10" id="y62e31437-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><chapeau>is—</chapeau><clause class="fontsize10" id="y62e31438-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>conducted by the Department of Health and Human Services, the Department of Defense, or the Department of Veterans Affairs; or</content></clause><clause class="fontsize10" id="y62e31439-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>funded partly or entirely by a grant, contract, cooperative agreement, or other transaction from the Department of Health and Human Services, the Department of Defense, or the Department of Veterans Affairs.</content></clause></subparagraph></paragraph><paragraph class="fontsize10" id="y62e3143a-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">“(3) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e3143b-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Notices.</p></sidenote><heading class="fontsize10 smallCaps">Expedited procedures<inline class="noSmallCaps">.—</inline></heading><subparagraph class="fontsize10" id="y62e3143c-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><heading class="fontsize10 smallCaps">Researcher with a current schedule i or ii research registration<inline class="noSmallCaps">.—</inline></heading><clause class="fontsize10" id="y62e3143d-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e3143e-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Time period.</p></sidenote><heading class="fontsize10 smallCaps">In general<inline class="noSmallCaps">.—</inline></heading><chapeau>If a practitioner is registered to conduct research with a controlled substance in schedule I or II, the practitioner may conduct research under this subsection on and after the date that is 30 days after the date on which the practitioner sends a notice to the Attorney General containing the following information, with respect to each substance with which the practitioner will conduct the research:</chapeau><subclause class="fontsize10" id="y62e3143f-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">“(I) </num><content>The chemical name of the substance.</content></subclause><subclause class="fontsize10" id="y62e31440-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="II">“(II) </num><content>The quantity of the substance to be used in the research.</content></subclause><subclause class="fontsize10" id="y62e31441-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="III">“(III) </num><chapeau>Demonstration that the research is in the category described in paragraph (2), which demonstration may be satisfied—</chapeau><item class="fontsize10" id="y62e31442-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658130"><num class="fontsize10" style="-uslm-lc:emspace2" value="aa">“(aa) </num><content>in the case of a grant, contract, cooperative agreement, or other transaction, <page identifier="/us/stat/139/412">139 STAT. 412</page>
or intramural research project, by identifying the sponsoring agency and supplying the number of the grant, contract, cooperative agreement, other transaction, or project; or</content></item><item class="fontsize10" id="y62e31443-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658130"><num class="fontsize10" style="-uslm-lc:emspace2" value="bb">“(bb) </num><content>in the case of an application under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<ref href="/us/usc/t21/s355/i">21 U.S.C. 355(i)</ref>), by supplying the application number and the sponsor of record on the application.</content></item></subclause><subclause class="fontsize10" id="y62e33b54-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="IV">“(IV) </num><content>Demonstration that the researcher is authorized to conduct research with respect to the substance under the laws of the State in which the research will take place.</content></subclause></clause><clause class="fontsize10" id="y62e33b55-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading class="fontsize10 smallCaps">Verification of information by hhs or va<inline class="noSmallCaps">.—</inline></heading><content>Upon request from the Attorney General, the Secretary of Health and Human Services, the Department of Defense, or the Secretary of Veterans Affairs, as appropriate, shall verify information submitted by an applicant under clause (i)(III).</content></clause></subparagraph><subparagraph class="fontsize10" id="y62e33b56-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><heading class="fontsize10 smallCaps">Researcher without a current schedule i or ii research registration<inline class="noSmallCaps">.—</inline></heading><clause class="fontsize10" id="y62e33b57-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><heading class="fontsize10 smallCaps">In general<inline class="noSmallCaps">.—</inline></heading><content>If a practitioner is not registered to conduct research with a controlled substance in schedule I or II, the practitioner may send a notice to the Attorney General containing the information listed in subparagraph (A)(i), with respect to each substance with which the practitioner will conduct the research.</content></clause><clause class="fontsize10" id="y62e33b58-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading class="fontsize10 smallCaps">Attorney general action<inline class="noSmallCaps">.—</inline></heading><chapeau>The Attorney General shall—</chapeau><subclause class="fontsize10" id="y62e33b59-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">“(I) </num><content>treat notice received under clause (i) as a sufficient application for a research registration; and</content></subclause><subclause class="fontsize10" id="y62e33b5a-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="II">“(II) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e33b5b-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Deadline.</p></sidenote><chapeau>not later than 45 days of receiving such a notice that contains all information required under subparagraph (A)(i)—</chapeau><item class="fontsize10" id="y62e33b5c-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658130"><num class="fontsize10" style="-uslm-lc:emspace2" value="aa">“(aa) </num><content>register the applicant; or</content></item><item class="fontsize10" id="y62e33b5d-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658130"><num class="fontsize10" style="-uslm-lc:emspace2" value="bb">“(bb) </num><content>serve an order to show cause upon the applicant in accordance with section 304(c).</content></item></subclause></clause></subparagraph></paragraph><paragraph class="fontsize10" id="y62e33b5e-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="4">“(4) </num><heading class="fontsize10 smallCaps">Electronic submissions<inline class="noSmallCaps">.—</inline></heading><content>The Attorney General shall provide a means to permit a practitioner to submit a notification under paragraph (3) electronically.</content></paragraph><paragraph class="fontsize10" id="y62e33b5f-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="5">“(5) </num><heading class="fontsize10 smallCaps">Limitation on amounts<inline class="noSmallCaps">.—</inline></heading><chapeau>A practitioner conducting research with a schedule I substance under this subsection may only possess the amounts of schedule I substance identified in—</chapeau><subparagraph class="fontsize10" id="y62e33b60-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>the notification to the Attorney General under paragraph (3); or</content></subparagraph><subparagraph class="fontsize10" id="y62e33b61-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e33b62-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Notification.</p></sidenote><chapeau>a supplemental notification that the practitioner may send if the practitioner needs additional amounts for the research, which supplemental notification shall include—</chapeau><clause class="fontsize10" id="y62e33b63-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>the name of the practitioner;</content></clause><clause class="fontsize10" id="y62e33b64-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>the additional quantity needed of the substance; and<page identifier="/us/stat/139/413">139 STAT. 413</page></content></clause><clause class="fontsize10" id="y62e33b65-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">“(iii) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e33b66-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Attestation.</p></sidenote><content>an attestation that the research to be conducted with the substance is consistent with the scope of the research that was the subject of the notification under paragraph (3).</content></clause></subparagraph></paragraph><paragraph class="fontsize10" id="y62e33b67-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="6">“(6) </num><heading class="fontsize10 smallCaps">Importation and exportation requirements not affected<inline class="noSmallCaps">.—</inline></heading><content>Nothing in this subsection alters the requirements of part A of title III, regarding the importation and exportation of controlled substances.</content></paragraph><paragraph class="fontsize10" id="y62e33b68-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="7">“(7) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e33b69-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Study.</p></sidenote><heading class="fontsize10 smallCaps">Inspector general report<inline class="noSmallCaps">.—</inline></heading><content>Not later than 1 year after the date of enactment of the Halt All Lethal Trafficking of Fentanyl Act, the Inspector General of the Department of Justice shall complete a study, and submit to Congress a report thereon, about research described in paragraph (2) of this subsection with fentanyl.”</content></paragraph></subsection></quotedContent>.</content></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y62e3627a-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/b" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><heading class="fontsize10 smallCaps">Separate Registrations Not Required for Additional Researcher in Same Institution<inline class="noSmallCaps">.—</inline></heading><paragraph class="fontsize10" id="y62e3627b-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/b/1" role="instruction" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><heading class="fontsize10 smallCaps">In general<inline class="noSmallCaps">.—</inline></heading><content>Section 302(c) of the Controlled Substances Act (<ref href="/us/usc/t21/s822/c">21 U.S.C. 822(c)</ref>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><paragraph class="indentUp0 fontsize10" id="y62e3898c-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="4">“(4) </num><chapeau>An agent or employee of a research institution that is conducting research with a controlled substance if—</chapeau><subparagraph class="fontsize10" id="y62e3898d-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>the agent or employee is acting within the scope of the professional practice of the agent or employee;</content></subparagraph><subparagraph class="fontsize10" id="y62e3898e-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>another agent or employee of the institution is registered to conduct research with a controlled substance in the same schedule;</content></subparagraph><subparagraph class="fontsize10" id="y62e3898f-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">“(C) </num><chapeau>the researcher who is so registered—</chapeau><clause class="fontsize10" id="y62e38990-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e38991-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Notification.</p></sidenote><content>informs the Attorney General of the name, position title, and employing institution of the agent or employee who is not separately registered;</content></clause><clause class="fontsize10" id="y62e38992-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>authorizes that agent or employee to perform research under the registration of the registered researcher; and</content></clause><clause class="fontsize10" id="y62e38993-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>affirms that any act taken by that agent or employee involving a controlled substance shall be attributable to the registered researcher, as if the researcher had directly committed the act, for purposes of any proceeding under section 304(a) to suspend or revoke the registration of the registered researcher; and</content></clause></subparagraph><subparagraph class="fontsize10" id="y62e3b0a4-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="D">“(D) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e3b0a5-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Deadline.</p></sidenote><content>the Attorney General does not, within 30 days of receiving the information, authorization, and affirmation described in subparagraph (C), refuse, for a reason listed in section 304(a), to allow the agent or employee to possess the substance without a separate registration.”</content></subparagraph></paragraph></quotedContent>.</content></paragraph><paragraph class="fontsize10" id="y62e3b0a6-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/b/2" role="instruction" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><heading class="fontsize10 smallCaps">Technical correction<inline class="noSmallCaps">.—</inline></heading><content>Section 302(c)(3) of the Controlled Substances Act (<ref href="/us/usc/t21/s822/c/3">21 U.S.C. 822(c)(3)</ref>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="delete">striking</amendingAction> “<quotedText>(25)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>(27)</quotedText>”.</content></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y62e3b0a7-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/c" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="c">(c) </num><heading class="fontsize10 smallCaps">Single Registration for Related Research Sites<inline class="noSmallCaps">.—</inline></heading><content>Section 302(e) of the Controlled Substances Act (<ref href="/us/usc/t21/s822/e">21 U.S.C. 822(e)</ref>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><paragraph class="indentUp0 firstIndent0 fontsize10" id="y62e425d8-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="4">“(4)</num><subparagraph class="inline" id="y62e425d9-6d77-11f0-a6a6-a93fc28e9cb7"><num value="A">(A) </num><chapeau>Notwithstanding paragraph (1), a person registered to conduct research with a controlled substance under section 303(g) may conduct the research under a single registration if—</chapeau><clause class="fontsize10" id="y62e425da-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><chapeau>the research occurs exclusively on sites all of which are—</chapeau><subclause class="fontsize10" id="y62e425db-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">“(I) </num><content>within the same city or county; and<page identifier="/us/stat/139/414">139 STAT. 414</page></content></subclause><subclause class="fontsize10" id="y62e425dc-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="II">“(II) </num><content>under the control of the same institution, organization, or agency; and</content></subclause></clause><clause class="fontsize10" id="y62e425dd-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e425de-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Notification.</p></sidenote><chapeau>before commencing the research, the researcher notifies the Attorney General of each site where—</chapeau><subclause class="fontsize10" id="y62e425df-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">“(I) </num><content>the research will be conducted; or</content></subclause><subclause class="fontsize10" id="y62e425e0-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="II">“(II) </num><content>the controlled substance will be stored or administered.</content></subclause></clause></subparagraph><subparagraph class="indentUp0 firstIndent0 fontsize10" id="y62e425e1-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><chapeau>A site described in subparagraph (A) shall be included in a registration described in that subparagraph only if the researcher has notified the Attorney General of the site—</chapeau><clause class="fontsize10" id="y62e425e2-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>in the application for the registration; or</content></clause><clause class="fontsize10" id="y62e425e3-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>before the research is conducted, or before the controlled substance is stored or administered, at the site.</content></clause></subparagraph><subparagraph class="indentUp0 firstIndent0 fontsize10" id="y62e425e4-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">“(C) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e425e5-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Regulations.</p></sidenote><chapeau>The Attorney General may, in consultation with the Secretary, issue regulations addressing, with respect to research sites described in subparagraph (A)—</chapeau><clause class="fontsize10" id="y62e425e6-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>the manner in which controlled substances may be delivered to the research sites;</content></clause><clause class="fontsize10" id="y62e425e7-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>the storage and security of controlled substances at the research sites;</content></clause><clause class="fontsize10" id="y62e425e8-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">“(iii) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e425e9-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Records.</p></sidenote><content>the maintenance of records for the research sites; and</content></clause><clause class="fontsize10" id="y62e425ea-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="iv">“(iv) </num><content>any other matters necessary to ensure effective controls against diversion at the research sites.”</content></clause></subparagraph></paragraph></quotedContent>.</content></subsection><subsection class="firstIndent0 fontsize10" id="y62e425eb-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/d" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="d">(d) </num><heading class="fontsize10 smallCaps">New Inspection Not Required in Certain Situations<inline class="noSmallCaps">.—</inline></heading><chapeau>Section 302(f) of the Controlled Substances Act (<ref href="/us/usc/t21/s822/f">21 U.S.C. 822(f)</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="y62e425ec-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/d/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>(f) The</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>(f)(1) The</quotedText>”; and</content></paragraph><paragraph class="fontsize10" id="y62e425ed-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/d/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><paragraph class="indentDown1 firstIndent0 fontsize10" id="y62e44bfe-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">“(2)</num><subparagraph class="inline" id="y62e44bff-6d77-11f0-a6a6-a93fc28e9cb7"><num value="A">(A) </num><content>If a person is registered to conduct research with a controlled substance and applies for a registration, or for a modification of a registration, to conduct research with a second controlled substance that is in the same schedule as the first controlled substance, or is in a schedule with a higher numerical designation than the schedule of the first controlled substance, a new inspection by the Attorney General of the registered location is not required.</content></subparagraph><subparagraph class="indentUp0 firstIndent0 fontsize10" id="y62e44c00-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>Nothing in subparagraph (A) shall prohibit the Attorney General from conducting an inspection that the Attorney General determines necessary to ensure that a registrant maintains effective controls against diversion.”</content></subparagraph></paragraph></quotedContent>.</content></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y62e44c01-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/e" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="e">(e) </num><heading class="fontsize10 smallCaps">Continuation of Research on Substances Newly Added to Schedule I<inline class="noSmallCaps">.—</inline></heading><content>Section 302 of the Controlled Substances Act (<ref href="/us/usc/t21/s822">21 U.S.C. 822</ref>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subsection class="firstIndent0 fontsize10" id="y62e49a22-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="h">“(h) </num><heading class="fontsize10 smallCaps">Continuation of Research on Substances Newly Added to Schedule I<inline class="noSmallCaps">.—</inline></heading><chapeau>If a person is conducting research on a substance when the substance is added to schedule I, and the person is already registered to conduct research with a controlled substance in schedule I—</chapeau><paragraph class="fontsize10" id="y62e49a23-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">“(1) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e49a24-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Deadline.</p></sidenote><content>not later than 90 days after the scheduling of the newly scheduled substance, the person shall submit a completed application for registration or modification of existing registration, to conduct research on the substance, in accordance with regulations issued by the Attorney General for purposes of this paragraph;</content></paragraph><paragraph class="fontsize10" id="y62e49a25-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">“(2) </num><chapeau>the person may, notwithstanding subsections (a) and (b), continue to conduct the research on the substance until—<page identifier="/us/stat/139/415">139 STAT. 415</page></chapeau><subparagraph class="fontsize10" id="y62e49a26-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>the person withdraws the application described in paragraph (1) of this subsection; or</content></subparagraph><subparagraph class="fontsize10" id="y62e49a27-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>the Attorney General serves on the person an order to show cause proposing the denial of the application under section 304(c);</content></subparagraph></paragraph><paragraph class="fontsize10" id="y62e49a28-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">“(3) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e49a29-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Hearing.</p><p class="leftAlign firstIndent0 fontsize8" id="x62e49a2a-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Deadline.</p></sidenote><content>if the Attorney General serves an order to show cause as described in paragraph (2)(B) and the person requests a hearing, the hearing shall be held on an expedited basis and not later than 45 days after the request is made, except that the hearing may be held at a later time if so requested by the person; and</content></paragraph><paragraph class="fontsize10" id="y62e49a2b-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="4">“(4) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e49a2c-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Records.</p></sidenote><content>if the person sends a copy of the application described in paragraph (1) to a manufacturer or distributor of the substance, receipt of the copy by the manufacturer or distributor shall constitute sufficient evidence that the person is authorized to receive the substance.”</content></paragraph></subsection></quotedContent>.</content></subsection><subsection class="firstIndent0 fontsize10" id="y62e4c13d-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/f" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="f">(f) </num><heading class="fontsize10 smallCaps">Treatment of Certain Manufacturing Activities as Coincident to Research<inline class="noSmallCaps">.—</inline></heading><content>Section 302 of the Controlled Substances Act (<ref href="/us/usc/t21/s822">21 U.S.C. 822</ref>), as amended by subsection (e), <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subsection class="firstIndent0 fontsize10" id="y62e50f5e-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><heading class="fontsize10 smallCaps">Treatment of Certain Manufacturing Activities as Coincident to Research<inline class="noSmallCaps">.—</inline></heading><paragraph class="fontsize10" id="y62e50f5f-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">“(1) </num><heading class="fontsize10 smallCaps">In general<inline class="noSmallCaps">.—</inline></heading><chapeau>Except as provided in paragraph (3), a person who is registered to perform research on a controlled substance may perform manufacturing activities with small quantities of that substance, including activities described in paragraph (2), without being required to obtain a manufacturing registration, if—</chapeau><subparagraph class="fontsize10" id="y62e50f60-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>the activities are performed for the purpose of the research; and</content></subparagraph><subparagraph class="fontsize10" id="y62e50f61-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><chapeau>the activities and the quantities of the substance involved in the activities are stated in—</chapeau><clause class="fontsize10" id="y62e50f62-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>a notification submitted to the Attorney General under section 303(n);</content></clause><clause class="fontsize10" id="y62e53673-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>a research protocol filed with an application for registration approval under section 303(g); or</content></clause><clause class="fontsize10" id="y62e53674-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">“(iii) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e53675-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Notification.</p></sidenote><chapeau>a notification to the Attorney General that includes—</chapeau><subclause class="fontsize10" id="y62e53676-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">“(I) </num><content>the name of the registrant; and</content></subclause><subclause class="fontsize10" id="y62e53677-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658128"><num class="fontsize10" style="-uslm-lc:emspace2" value="II">“(II) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e53678-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Attestation.</p></sidenote><content>an attestation that the research to be conducted with the small quantities of manufactured substance is consistent with the scope of the research that is the basis for the registration.</content></subclause></clause></subparagraph></paragraph><paragraph class="fontsize10" id="y62e53679-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">“(2) </num><heading class="fontsize10 smallCaps">Activities included<inline class="noSmallCaps">.—</inline></heading><chapeau>Activities permitted under paragraph (1) include—</chapeau><subparagraph class="fontsize10" id="y62e5367a-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><chapeau>processing the substance to create extracts, tinctures, oils, solutions, derivatives, or other forms of the substance consistent with—</chapeau><clause class="fontsize10" id="y62e5367b-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>the information provided as part of a notification submitted to the Attorney General under section 303(n); or</content></clause><clause class="fontsize10" id="y62e5367c-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>a research protocol filed with an application for registration approval under section 303(g); and</content></clause></subparagraph><subparagraph class="fontsize10" id="y62e5367d-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>dosage form development studies performed for the purpose of requesting an investigational new drug exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<ref href="/us/usc/t21/s355/i">21 U.S.C. 355(i)</ref>).<page identifier="/us/stat/139/416">139 STAT. 416</page></content></subparagraph></paragraph><paragraph class="fontsize10" id="y62e5367e-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">“(3) </num><heading class="fontsize10 smallCaps">Exception regarding marihuana<inline class="noSmallCaps">.—</inline></heading><content>The authority under paragraph (1) to manufacture substances does not include the authority to grow marihuana.”</content></paragraph></subsection></quotedContent>.</content></subsection><subsection class="firstIndent0 fontsize10" id="y62e5367f-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s3/g" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="g">(g) </num><heading class="fontsize10 smallCaps">Transparency Regarding Special Procedures<inline class="noSmallCaps">.—</inline></heading><content>Section 303 of the Controlled Substances Act (<ref href="/us/usc/t21/s823">21 U.S.C. 823</ref>), as amended by subsection (a), <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subsection class="firstIndent0 fontsize10" id="y62e55d90-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="o">“(o) </num><heading class="fontsize10 smallCaps">Transparency Regarding Special Procedures<inline class="noSmallCaps">.—</inline></heading><paragraph class="fontsize10" id="y62e55d91-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">“(1) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e55d92-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Determination.</p><p class="leftAlign firstIndent0 fontsize8" id="x62e55d93-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Public information.</p><p class="leftAlign firstIndent0 fontsize8" id="x62e55d94-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Web posting.</p></sidenote><heading class="fontsize10 smallCaps">In general<inline class="noSmallCaps">.—</inline></heading><chapeau>If the Attorney General determines, with respect to a controlled substance, that an application by a practitioner to conduct research with the substance should be considered under a process, or subject to criteria, different from the process or criteria applicable to applications to conduct research with other controlled substances in the same schedule, the Attorney General shall make public, including by posting on the website of the Drug Enforcement Administration—</chapeau><subparagraph class="fontsize10" id="y62e584a5-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>the identities of all substances for which such determinations have been made;</content></subparagraph><subparagraph class="fontsize10" id="y62e584a6-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e584a7-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Process.</p><p class="leftAlign firstIndent0 fontsize8" id="x62e584a8-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Criteria.</p><p class="leftAlign firstIndent0 fontsize8" id="x62e584a9-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Applicability.</p></sidenote><content>the process and criteria that shall be applied to applications to conduct research with those substances; and</content></subparagraph><subparagraph class="fontsize10" id="y62e584aa-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">“(C) </num><content>how the process and criteria described in subparagraph (B) differ from the process and criteria applicable to applications to conduct research with other controlled substances in the same schedule.</content></subparagraph></paragraph><paragraph class="fontsize10" id="y62e584ab-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">“(2) </num><heading class="fontsize10 smallCaps">Timing of posting<inline class="noSmallCaps">.—</inline></heading><content>The Attorney General shall make information described in paragraph (1) public upon making a determination described in that paragraph, regardless of whether a practitioner has submitted such an application at that time.”</content></paragraph></subsection></quotedContent>.</content></subsection></section>
<section id="d648e926" identifier="/us/pl/119/26/s4" style="-uslm-lc:I658141"><num class="fontsize12" value="4">SEC. 4. </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e584ac-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Effective date.</p><p class="leftAlign firstIndent0 fontsize8" id="x62e584ad-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t21/s822">21 USC 822 note</ref>.</p></sidenote><heading>TECHNICAL CORRECTION ON CONTROLLED SUBSTANCES DISPENSING.</heading><chapeau class="indentUp0 firstIndent0 fontsize10" id="x62e66f0e-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658120">  Effective as if included in the enactment of <ref href="/us/pl/117/328">Public Law 117–328</ref>—</chapeau><paragraph class="fontsize10" id="y62e66f0f-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/1" role="instruction" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content><ref href="/us/pl/117/328/dFF/s1252/a">section 1252(a) of division FF of Public Law 117–328</ref> (<ref href="/us/stat/136/5681">136 Stat. 5681</ref>)<sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e66f10-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t21/s822">21 USC 822</ref>.</p></sidenote> <amendingAction type="amend">is amended</amendingAction>, in the matter being inserted into section 302(e) of the Controlled Substances Act, by <amendingAction type="delete">striking</amendingAction> “<quotedText>303(g)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>303(h)</quotedText>”;</content></paragraph><paragraph class="fontsize10" id="y62e66f11-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2" role="instruction" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><chapeau><ref href="/us/pl/117/328/dFF/s1262">section 1262 of division FF of Public Law 117–328</ref> (<ref href="/us/stat/136/5681">136 Stat. 5681</ref>)<sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e66f12-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t21/s823">21 USC 823</ref>.</p></sidenote> <amendingAction type="amend">is amended</amendingAction>—</chapeau><subparagraph class="fontsize10" id="y62e66f13-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><chapeau>in subsection (a)—</chapeau><clause class="fontsize10" id="y62e66f14-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/A/i" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><content>in the matter preceding paragraph (1), by <amendingAction type="delete">striking</amendingAction> “<quotedText>303(g)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>303(h)</quotedText>”;</content></clause><clause class="fontsize10" id="y62e66f15-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/A/ii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>in the matter being stricken by subsection (a)(2), by <amendingAction type="delete">striking</amendingAction> “<quotedText>(g)(1)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>(h)(1)</quotedText>”; and</content></clause><clause class="fontsize10" id="y62e66f16-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/A/iii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">(iii) </num><content>in the matter being inserted by subsection (a)(2), by <amendingAction type="delete">striking</amendingAction> “<quotedText>(g) Practitioners</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>(h) Practitioners</quotedText>”; and</content></clause></subparagraph><subparagraph class="fontsize10" id="y62e66f17-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><chapeau>in subsection (b)—</chapeau><clause class="fontsize10" id="y62e66f18-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/B/i" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e66f19-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t21/s824">21 USC 824</ref>.</p></sidenote><content>in the matter being stricken by paragraph (1), by <amendingAction type="delete">striking</amendingAction> “<quotedText>303(g)(1)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>303(h)(1)</quotedText>”;</content></clause><clause class="fontsize10" id="y62e66f1a-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/B/ii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>in the matter being inserted by paragraph (1), by <amendingAction type="delete">striking</amendingAction> “<quotedText>303(g)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>303(h)</quotedText>”;</content></clause><clause class="fontsize10" id="y62e66f1b-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/B/iii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">(iii) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e66f1c-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t21/s829a">21 USC 829a</ref>.</p></sidenote><content>in the matter being stricken by paragraph (2)(A), by <amendingAction type="delete">striking</amendingAction> “<quotedText>303(g)(2)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>303(h)(2)</quotedText>”;<page identifier="/us/stat/139/417">139 STAT. 417</page></content></clause><clause class="fontsize10" id="y62e66f1d-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/B/iv" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iv">(iv) </num><content>in the matter being stricken by paragraph (3)<sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e66f1e-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t42">42 USC </ref></p><p class="leftAlign firstIndent0 fontsize8" id="x62e6962f-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">290bb–36d.</p></sidenote>, by <amendingAction type="delete">striking</amendingAction> “<quotedText>303(g)(2)(B)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>303(h)(2)(B)</quotedText>”;</content></clause><clause class="fontsize10" id="y62e69630-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/B/v" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="v">(v) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e69631-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t42/s1395">42 USC 1395</ref><i>l</i>.</p></sidenote><content>in the matter being stricken by paragraph (5), by <amendingAction type="delete">striking</amendingAction> “<quotedText>303(g)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>303(h)</quotedText>”; and</content></clause><clause class="fontsize10" id="y62e69632-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/2/B/vi" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="vi">(vi) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e69633-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t42/s1395m">42 USC 1395m</ref>.</p></sidenote><content>in the matter being stricken by paragraph (6), by <amendingAction type="delete">striking</amendingAction> “<quotedText>303(g)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>303(h)</quotedText>”; and</content></clause></subparagraph></paragraph><paragraph class="fontsize10" id="y62e69634-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/3" role="instruction" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><chapeau><ref href="/us/pl/117/328/dFF/s1263/b">section 1263(b) of division FF of Public Law 117–328</ref> (<ref href="/us/stat/136/5685">136 Stat. 5685</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><subparagraph class="fontsize10" id="y62e69635-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/3/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>303(g)(2)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>303(h)(2)</quotedText>”; and</content></subparagraph><subparagraph class="fontsize10" id="y62e69636-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s4/3/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>(<ref href="/us/usc/t21/s823/g/2">21 U.S.C. 823(g)(2)</ref>)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>(<ref href="/us/usc/t21/s823/h/2">21 U.S.C. 823(h)(2)</ref>)</quotedText>”.</content></subparagraph></paragraph></section>
<section id="d648e1165" identifier="/us/pl/119/26/s5" style="-uslm-lc:I658141"><num class="fontsize12" value="5">SEC. 5. </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e6bd47-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t21/s812">21 USC 812 note</ref>.</p></sidenote><heading>RULEMAKING.</heading><subsection class="firstIndent0 fontsize10" id="y62e70b68-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s5/a" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10 smallCaps">Interim Final Rules<inline class="noSmallCaps">.—</inline></heading><chapeau>The Attorney General—</chapeau><paragraph class="fontsize10" id="y62e70b69-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s5/a/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e70b6a-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Deadline.</p></sidenote><content>shall, not later than 6 months after the date of enactment of this Act, issue rules to implement this Act and the amendments made by this Act; and</content></paragraph><paragraph class="fontsize10" id="y62e70b6b-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s5/a/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>may issue the rules under paragraph (1) as interim final rules.</content></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y62e70b6c-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s5/b" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><heading class="fontsize10 smallCaps">Procedure for Final Rule<inline class="noSmallCaps">.—</inline></heading><paragraph class="fontsize10" id="y62e70b6d-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s5/b/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><heading class="fontsize10 smallCaps">Effectiveness of interim final rules<inline class="noSmallCaps">.—</inline></heading><content>A rule issued by the Attorney General as an interim final rule under subsection (a) shall become immediately effective as an interim final rule without requiring the Attorney General to demonstrate good cause therefor, notwithstanding subparagraph (B) of the undesignated matter following paragraph (4) of <ref href="/us/usc/t5/s553/b">section 553(b) of title 5, United States Code</ref>.</content></paragraph><paragraph class="fontsize10" id="y62e70b6e-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s5/b/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><heading class="fontsize10 smallCaps">Opportunity for comment and hearing<inline class="noSmallCaps">.—</inline></heading><content>An interim final rule issued under subsection (a) shall give interested persons the opportunity to comment and to request a hearing.</content></paragraph><paragraph class="fontsize10" id="y62e7327f-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s5/b/3" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><heading class="fontsize10 smallCaps">Final rule<inline class="noSmallCaps">.—</inline></heading><content>After the conclusion of such proceedings, the Attorney General shall issue a final rule to implement this Act and the amendments made by this Act in accordance with <ref href="/us/usc/t5/s553">section 553 of title 5, United States Code</ref>.</content></paragraph></subsection></section>
<section id="d648e1233" identifier="/us/pl/119/26/s6" style="-uslm-lc:I658141"><num class="fontsize12" value="6">SEC. 6. </num><heading>PENALTIES.</heading><subsection class="firstIndent0 fontsize10" id="y62e780a0-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s6/a" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10 smallCaps">In General<inline class="noSmallCaps">.—</inline></heading><chapeau>Section 401(b)(1) of the Controlled Substances Act (<ref href="/us/usc/t21/s841/b/1">21 U.S.C. 841(b)(1)</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="y62e780a1-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s6/a/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>in subparagraph (A)(vi), by <amendingAction type="insert">inserting</amendingAction> “<quotedText>or a fentanyl-related substance</quotedText>” after “<quotedText>any analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide</quotedText>”; and</content></paragraph><paragraph class="fontsize10" id="y62e780a2-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s6/a/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>in subparagraph (B)(vi), by <amendingAction type="insert">inserting</amendingAction> “<quotedText>or a fentanyl-related substance</quotedText>” after “<quotedText>any analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide</quotedText>”.</content></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y62e780a3-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s6/b" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><heading class="fontsize10 smallCaps">Importation and Exportation<inline class="noSmallCaps">.—</inline></heading><chapeau>Section 1010(b) of the Controlled Substances Import and Export Act (<ref href="/us/usc/t21/s960/b">21 U.S.C. 960(b)</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="y62e780a4-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s6/b/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>in paragraph (1)(F), by <amendingAction type="insert">inserting</amendingAction> “<quotedText>or a fentanyl-related substance</quotedText>” after “<quotedText>any analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide</quotedText>”; and</content></paragraph><paragraph class="fontsize10" id="y62e7a7b5-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s6/b/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>in paragraph (2)(F), by <amendingAction type="insert">inserting</amendingAction> “<quotedText>or a fentanyl-related substance</quotedText>” after “<quotedText>any analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide</quotedText>”.</content></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y62e7a7b6-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s6/c" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="c">(c) </num><heading class="fontsize10 smallCaps">Definition of Fentanyl-related Substance<inline class="noSmallCaps">.—</inline></heading><content>Section 102 of the Controlled Substances Act (<ref href="/us/usc/t21/s802">21 U.S.C. 802</ref>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<page identifier="/us/stat/139/418">139 STAT. 418</page>
<quotedContent><paragraph class="indentUp0 firstIndent0 fontsize10" id="y62e7a7b7-6d77-11f0-a6a6-a93fc28e9cb7" role="definitions" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="60">“(60) </num><content>The term ‘<term>fentanyl-related substance</term>’ has the meaning given the term in subsection (e)(2) of schedule I of section 202(c).”</content></paragraph></quotedContent>.</content></subsection></section>
<section id="d648e1327" identifier="/us/pl/119/26/s7" style="-uslm-lc:I658141"><num class="fontsize12" value="7">SEC. 7. </num><heading>APPLICABILITY; OTHER MATTERS.</heading><subsection class="firstIndent0 fontsize10" id="y62e7cec8-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s7/a" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e7f5d9-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180">Effective date.</p><p class="leftAlign firstIndent0 fontsize8" id="x62e7f5da-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t21/s812">21 USC 812 note</ref>.</p></sidenote><heading class="fontsize10 smallCaps">In General<inline class="noSmallCaps">.—</inline></heading><content>Irrespective of the date on which the rules required by section 5 are finalized, the amendments made by this Act apply beginning as of the date of enactment of this Act.</content></subsection><subsection class="firstIndent0 fontsize10" id="y62e7f5db-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s7/b" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62e7f5dc-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658180"><ref href="/us/usc/t21/s841">21 USC 841 note</ref>.</p></sidenote><heading class="fontsize10 smallCaps">Rule of Construction<inline class="noSmallCaps">.—</inline></heading><content>Nothing in the amendments made by this Act may be construed as evidence that, in applying sections 401(b)(1) of the Controlled Substances Act (<ref href="/us/usc/t21/s841/b/1">21 U.S.C. 841(b)(1)</ref>) and 1010(b) of the Controlled Substances Import and Export Act (<ref href="/us/usc/t21/s960/b">21 U.S.C. 960(b)</ref>) with respect to conduct occurring before the date of the enactment of this Act, a fentanyl-related substance (as defined by such amendments) is not an analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide.</content></subsection><subsection class="firstIndent0 fontsize10" id="y62e7f5dd-6d77-11f0-a6a6-a93fc28e9cb7" identifier="/us/pl/119/26/s7/c" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="c">(c) </num><heading class="fontsize10 smallCaps">Sense of Congress<inline class="noSmallCaps">.—</inline></heading><content>Congress agrees with the interpretation of the Controlled Substances Act (<ref href="/us/usc/t21/s801/etseq">21 U.S.C. 801 et seq.</ref>) in United States v. McCray, 346 F. Supp. 3d 363 (W.D.N.Y. 2018).</content></subsection></section>
<action>
<actionDescription style="-uslm-lc:I658030">Approved</actionDescription> <date date="2025-07-16">July 16, 2025</date>.</action>
</main>
<legislativeHistory>
<heading style="-uslm-lc:I658031"><inline class="underline">LEGISLATIVE HISTORY</inline>—<ref href="/us/bill/119/s/331">S. 331</ref>:</heading>
<note>
<heading style="-uslm-lc:I658032">CONGRESSIONAL RECORD, Vol. 171 (2025):</heading>
<p class="indentUp4 firstIndent-1" id="x62e7f5de-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658035">Mar. 10, 11, 13, 14, considered and passed Senate.</p><p class="indentUp4 firstIndent-1" id="x62e7f5df-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658035">June 11, 12, considered and passed House.</p></note>
<note>
<heading style="-uslm-lc:I658032">DAILY COMPILATION OF PRESIDENTIAL DOCUMENTS (2025):</heading>
<p class="indentUp4 firstIndent-1" id="x62e7f5e0-6d77-11f0-a6a6-a93fc28e9cb7" style="-uslm-lc:I658035">July 16, Presidential remarks.</p></note>
</legislativeHistory>
<endMarker>○</endMarker>
</pLaw>